FDA panel backs Moderna's mRNA flu vaccine for older adults

Why it matters locally: The potential approval of Moderna's mRNA flu vaccine for older adults could significantly impact public health initiatives in New York, where over 3.3 million residents are aged 60 and older. This new vaccine technology could offer faster production and potentially improved protection against seasonal influenza for a vulnerable population.

An FDA advisory panel recommended approval Thursday for Moderna's mRNA flu vaccine targeting older adults, marking a potential expansion of messenger RNA technology into seasonal influenza prevention. The panel's recommendation does not guarantee FDA approval but carries significant weight in the agency's decision-making process. The FDA typically follows advisory panel recommendations, though the agency retains final authority over vaccine authorizations. Moderna developed the vaccine using the same mRNA platform the company employed for its COVID-19 vaccine. The shot instructs human cells to produce a protein that trains the immune system to recognize influenza viruses. The recommendation focused on use among adults 60 and older. Moderna submitted data from clinical trials evaluating the vaccine's safety and effectiveness in that population. Flu vaccines currently available use older production methods, including egg-based and cell-based approaches. An mRNA flu vaccine would offer manufacturers a faster production timeline, potentially allowing quicker response to emerging virus strains. The FDA typically reviews advisory panel recommendations within weeks. If the agency approves the vaccine, Moderna would then work with healthcare providers and insurers to distribute it. Seasonal influenza infects millions of Americans annually and causes thousands of deaths, with older adults facing the highest risk of severe illness. Current flu vaccination rates among seniors remain below public health targets.